SIBN
SI-BONEยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SIBN Profile
Si-Bone, Inc.
A developer of proprietary minimally invasive surgical implant system to treat sacroiliac joint dysfunction
Healthcare Equipment and Supplies
03/18/2008
10/17/2018
NASDAQ Stock Exchange
349
12-31
Common stock
471 El Camino Real, Suite 101, Santa Clara, California 95050
--
SI-BONE, Inc., was incorporated in Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The company is a medical device company that addresses musculoskeletal diseases in sacropelvic anatomy. Leveraging knowledge of pelvic anatomy and biomechanics, the company has pioneered proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and address unmet clinical needs in pelvic fusion, fixation and pelvic fracture management. The company's products include a range of patented titanium implants and devices for implanting them. Since the launch of the first generation iFuse in 2009, the company has launched three new implant product lines, iFuse-3D in 2017, iFuse-TORQ in 2021 and iFuse Bedrock Granite in 2022. In the United States, the company's iFuse, iFuse-3D and iFuse-TORQ implant systems are licensed for use in sacroiliac joint dysfunction and fusion, adult deformities and degeneration, and pelvic trauma.
